News & Updates

Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.

For patients with Hodgkin’s lymphoma who have completed a first-line chemotherapy regimen that includes doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), neutrophil and lymphocyte counts are predictive of disease prognosis, as reported in a study from Singapore.

In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.

Combination therapy using yttrium 90 (Y90) radioembolization and sorafenib/nivolumab for patients with hepatocellular carcinoma (HCC), with hepatic vein (HV) or inferior vena cava (IVC) invasion, results in better outcomes, as indicated by increased response rates, overall survival (OS), and progression-free survival (PFS) benefits, a study has found.

In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.

Rucaparib significantly improves radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel, abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring BRCA alterations whose disease has progressed after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI), results of the phase III TRITON3 trial have shown.

The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.